EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2013 (No.1)
PB 67 of 2013
Authority
Subsection 100(1) of the National Health Act 1953 (the Act) enables the Minister to make special arrangements for the supply of pharmaceutical benefits. Subsection 100(2) of the Act provides that the Minister may vary or revoke a special arrangement made under subsection 100(1).
Subsection 100(3) of the Act provides that Part VII of the Act, and instruments made for the purposes of Part VII have effect subject to a special arrangement made under subsection 100(1).
Purpose
The purpose of this legislative instrument, made under subsections 100(1) and (2) of the Act, is to amend the National Health (Botulinum Toxin Program) Special Arrangement 2011 (PB 89 of 2011) (the Special Arrangement) to make changes to the special arrangement relating to the Botulinum Toxin Program.
The purpose of the Special Arrangement is to allow for botulinum toxin to be supplied to specific patients through eligible medical practitioners.
Schedule 1 to this instrument inserts one new treatment condition for the treatment of urinary incontinence due to neurogenic detrusor overactivity under the Special Arrangement to commence on 1 October 2013. Patients must have multiple sclerosis or have a spinal cord injury, or be aged 18 years or over and have spina bifida to qualify for treatment with the listed brand ‘Botox’ under the Special Arrangement.
In addition this instrument makes consequential changes to reflect the new treatment condition.
Consultation
The addition of these amendments was made having regard to advice provided by the Pharmaceutical Benefits Advisory Committee (PBAC). PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.
PBAC has broad representation with members appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists; at least one member is selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of PBAC, and that would enable them to contribute meaningfully to the deliberations of PBAC. When recommending the listing of a medicine on the Pharmaceutical Benefits Scheme (PBS), PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.
Pharmaceutical companies were consulted throughout the process for additions and changes to listings on the PBS and for this Special Arrangement. This includes consultation through the PBAC process, which provides for consumers making submissions to the Committee in respect of proposals to be discussed, and agreement to final listing details.
General
This instrument commences on 1 October 2013.
This instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.
ATTACHMENT
PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (BOTULINUM TOXIN PROGRAM) SPECIAL ARRANGEMENT AMENDMENT INSTRUMENT 2013 (No. 1)
Section 1 Name of Instrument
This section provides that this Instrument is the National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2013 (No. 1) and that it may also be cited as PB 67 of 2013.
Section 2 Commencement
This section provides that this Instrument commences on 1 October 2013.
Section 3 Amendments to PB 89 of 2011
This section provides that Schedule 1 amends the National Health (Botulinum Toxin Program) Special Arrangement 2011 (PB 89 of 2011) (the Special Arrangement).
Section 4 Transitional
This section provides alternative information that must be provided by medical practitioners who are specialists in urology or urogynaecology who have sought authorisation to administer botulinum toxin pharmaceutical benefits for the treatment of urinary incontinence due to neurogenic detrusor overactivity prior to commencement of this Instrument. These practitioners in particular do not have to provide evidence of supervision. These practitioners are eligible to administer botulinum toxin pharmaceutical benefits for the treatment of urinary incontinence due to neurogenic detrusor overactivity if they provide the alternative information to the Chief Executive Medicare.
Schedule 1
Item 1 makes a consequential amendment to subsection 10(1) of the Special Arrangement to reflect the insertion of new section 12A.
Item 2 inserts a new section 12A into the Special Arrangement that provides the criteria a person needs to meet to be eligible to receive a botulinum toxin pharmaceutical benefit for the treatment of urinary incontinence due to neurogenic detrusor overactivity.
Item 3 makes a consequential amendment to subsection 18(3) of the Special Arrangement to reflect the insertion of subsection 18(6) that provides another exception to the provision of evidence of the applicant practitioner’s training.
Item 4 inserts a new subsection 18(6) into the Special Arrangement providing the evidence of training that needs to be provided for authorisation of an applicant practitioner to administer botulinum toxin pharmaceutical benefits for the treatment of urinary incontinence due to neurogenic detrusor overactivity.
Item 5 amends schedule 3 of the Special Arrangement by adding a new treatment condition for the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who have multiple sclerosis, or a spinal cord injury, or who are 18 years or older and have spina bifida.